Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

0 search results for

Suggestions within Pfizer.com

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

July 2024

07.11.2024
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
- Research and Pipeline
- Research

June 2024

06.12.2024
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
- Research
06.01.2024
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Prescription Medicines
- Research
06.01.2024
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
- Medicines
- Research

May 2024

05.31.2024
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
- Research

March 2024

03.12.2024
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Medicines
- Research

November 2023

11.02.2023
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
- Research and Pipeline
- Research

June 2023

06.26.2023
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
- Research and Pipeline
- Research
06.01.2023
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Research and Pipeline
- Research

December 2022

12.29.2022
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
- Medicines
- Research
12.01.2022
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
12.01.2022
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

Page 1
Current page 2
Page 3
Page 4
Page 5

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube